cyclopropyl methyl ketone pyrrolidine enamine | 23735-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: cyclopropyl methyl ketone pyrrolidine enamine
• 英文别名: 1-(1-cyclopropyl-vinyl)-pyrrolidine；1-(1-cyclopropylvinyl)-pyrrolidine；1-(1-cyclopropylethenyl)pyrrolidine
• CAS: 23735-64-0
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: MBWGALUWKFBLQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  异烟酸酰氯 、 cyclopropyl methyl ketone pyrrolidine enamine 在 三乙胺 作用下， 以 乙醇 、 水 为溶剂， 生成 4-[5-环丙基-5-(1-吡咯烷基)-2-异恶唑啉-3-基]吡啶
  参考文献：
  名称：

  Substituted pyridines and diazines and methods of preparing the same

  摘要：

  本文描述了从相应的环丙基单氧化胺制备环丙基异噁唑基吡啶和环丙基异噁唑基二氮杂苯。这些产物在治疗疼痛、肌肉痉挛、炎症、焦虑或紧张方面具有用途。

  公开号：

  US03957805A1

文献信息

• [EN] SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS<br/>[FR] 2-QUINOLYLE-OXAZOLES SUBSTITUÉS UTILES COMME INHIBITEURS DU PDE4
  申请人：SCHERING CORP

  公开号：WO2005116009A1

  公开（公告）日：2005-12-08

  The invention claims compounds of the: (formula I); wherein: (formula II) is a 5-membered heteroaryl; X is S or O; R1 is H, alkyl, cycloalkyl, cylcoalkylalkyl-, -CH2F, -CHF2, -CF3, -C(O)alkyl or -C(O)NR18R19; R3 and R4 H, alkyl, hydroxyalkyl or -C(O)Oalkyl; R5 and R6 are H, alkyl, hydroxyalkyl, alkoxyalkyl, mercaptoalkyl, -CH2F, -CHF2, -CF3, -C(O)OH or -C(O)Oalkyl; R7 is H, alkyl, alkenyl, hydroxyalkyl, cycloalkyl, alkoxyalkyl, aminoalkyl, (R17-phenyl)alkyl or -CH2-C(O)-O-alkyl; and R8 comprises alkyl, heteroaryl, phenyl or cycloalkyl, or heterocycloalkyl, all optionally substituted, or a cycloalkyl- or heterocycloalkyl-substituted amide; or R7 and R8 and the nitrogen to which they are attached together form an optionally substituted ring; and the remaining variables are as defined in the specification. Also claimed are pharmaceutical compositions, the use of the compounds as PDE4 inhibitors, and combinations with other actives.

  该发明声明了以下化合物：(化学式I)；其中：(化学式II)是一种5-成员杂环芳基；X为S或O；R1为H，烷基，环烷基，环烷基烷基，-CH2F，-CHF2，-CF3，-C(O)烷基或-C(O)NR18R19；R3和R4为H，烷基，羟基烷基或-C(O)O烷基；R5和R6为H，烷基，羟基烷基，烷氧基烷基，巯基烷基，-CH2F，-CHF2，-CF3，-C(O)OH或-C(O)O烷基；R7为H，烷基，烯基，羟基烷基，环烷基，烷氧基烷基，氨基烷基，(R17-苯基)烷基或-CH2-C(O)-O-烷基；R8包括烷基，杂环芳基，苯基或环烷基，或杂环烷基，均可选择性取代，或环烷基或杂环烷基取代的酰胺；或R7和R8及它们附着的氮一起形成一个可选择性取代的环；其余变量如规范中所定义。还声明了药物组合物，将这些化合物用作PDE4抑制剂，并与其他活性物质组合使用。
• General Scope of 1,4-Diastereoselective Additions to a 2(3<i>H</i>)-Quinazolinone:  Practical Preparation of HIV Therapeutics
  作者：Nicholas A. Magnus、Pat N. Confalone、Louis Storace、Mona Patel、Christopher C. Wood、Wayne P. Davis、Rodney L. Parsons

  DOI：10.1021/jo0263162

  日期：2003.2.1

  The practical and highly diastereoselective syntheses of CF3-substituted dihydroquinazolinones via 1,4-additions of nucleophiles to chiral auxiliary substituted 2(3H)-quinazolinones is described. This methodology is applied to the syntheses of the NNRTIs (nonnucleoside reverse transcriptase inhibitors) DPC 961 (1) and DPC 083 (2), which are useful for the treatment of HIV (human immunodeficiency virus). The synthesis of DPC 961 (1) requires three steps, proceeds in >55% overall yield from the keto-aniline 9, and gives synthetic access to DPC 083 (2). In addition, the scope of the new diastereoselective 1,4-addition chemistry is investigated. The first preparation of DPC 961 (1) described in this paper is a derivatization fractional crystallization protocol.
• Cyclopropane in photochemistry. I. Photochemistry of 4,4-dicyclopropylcyclohexenone
  作者：Roger C. Hahan、Gerald W. Jones

  DOI：10.1021/ja00746a024

  日期：1971.8
• Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
  申请人：Schering Corporation

  公开号：EP1758883B1

  公开（公告）日：2011-11-02
• US3957805A
  申请人：——

  公开号：US3957805A

  公开（公告）日：1976-05-18